Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04815096 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Imaging Immune Activation in COVID-19

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 1, 2025 to Oct 1, 2027
    • Primary endpoint revised
    • Study completion date: Oct 1, 2025 to Oct 1, 2028
    • Secondary endpoints revised (3)
    v8
  2. Phase: Early Phase 1 to Phase 2v7 Show 5 more changesShow less
    • Enrollment target: 20 to 80
    • Primary and study completion dates: Oct 1, 2024 to Oct 1, 2025
    • Primary endpoint revised
    • Secondary endpoints revised (3)
    • Study description expanded, about 6 words
  3. Primary and study completion dates: Mar 1, 2023 to Oct 1, 2024v6
  4. 2 versions Re-verified since Aug 2, 2021, no change to tracked fieldsv4-v5
  5. Start date: Mar 15, 2021 to Apr 15, 2021v3
  6. Trial status: Enrolling by Invitation to Recruiting
    • Site details revised
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single center, single arm exploratory imaging study involving up to two intravenous microdoses of \[18F\]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent COVID-19. Up to 80 participants will be enrolled over an accrual period of approximately 48 months.
Trial Details
NCT Number NCT04815096
Lead Sponsor CellSight Technologies, Inc.
Collaborators: University of California, San Francisco
Conditions
(from sponsor)		 Covid19, SARS-CoV Infection
Related terms COVID-19, Severe Acute Respiratory Syndrome
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov